checkAd

     273  0 Kommentare Verrica Issues Statement in Support of FDA’s Warning Letters to Manufacturers and Retailers for Producing and Selling Unapproved Products for the Treatment of Molluscum Contagiosum

    Verrica’s product YCANTH is the first and only FDA-approved treatment for molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children

    YCANTH is expected to be available for commercial use by licensed healthcare providers by September 2023

    WEST CHESTER, Pa., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, issued a statement today in support of the U.S. Food and Drug Administration’s (“FDA’s”) recent action against retailers and manufacturers of unapproved products for the treatment of molluscum contagiosum.

    “On the heels of the June 1, 2023 FDA warning to consumers not to use unapproved products for the treatment of molluscum contagiosum, we are pleased the FDA is taking additional measures against these unapproved products,” said Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals. “It is clear that the FDA views molluscum as a serious health problem that requires medical intervention with therapies that have been rigorously tested and properly reviewed. Verrica has conducted two Phase 3 trials to demonstrate the clinical safety and efficacy of YCANTH, so that the millions of people, primarily children, who suffer from this viral infection can finally receive a safe, effective, and FDA-approved treatment for their condition.”

    About Molluscum Contagiosum (Molluscum)
    Molluscum is a highly contagious viral skin disease that affects approximately six million people — primarily children — in the United States. Molluscum is caused by a pox virus that produces distinctive raised, skin-toned-to-pink-colored lesions that can cause pain, inflammation, itching and bacterial infection. It is easily transmitted through direct skin-to-skin contact or through fomites (objects that carry the disease like toys, towels or wet surfaces) and can spread to other parts of the body or to other people, including siblings. The lesions can be found on most areas of the body and may carry substantial social stigma. Without treatment, molluscum can last for an average of 13 months, and in some cases, up to several years.

    Seite 1 von 4



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Verrica Issues Statement in Support of FDA’s Warning Letters to Manufacturers and Retailers for Producing and Selling Unapproved Products for the Treatment of Molluscum Contagiosum Verrica’s product YCANTH is the first and only FDA-approved treatment for molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children YCANTH is expected to be …